Jason Somer Sells 10,000 Shares of Inogen, Inc. (NASDAQ:INGN) Stock

Inogen, Inc. (NASDAQ:INGN - Get Free Report) EVP Jason Somer sold 10,000 shares of the company's stock in a transaction on Friday, May 10th. The shares were sold at an average price of $8.56, for a total transaction of $85,600.00. Following the completion of the sale, the executive vice president now directly owns 4,452 shares in the company, valued at $38,109.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Inogen Price Performance

Shares of INGN traded up $0.11 during trading hours on Tuesday, hitting $8.92. The stock had a trading volume of 342,698 shares, compared to its average volume of 529,110. Inogen, Inc. has a 1-year low of $4.13 and a 1-year high of $11.98. The firm has a market capitalization of $210.33 million, a P/E ratio of -2.15 and a beta of 1.10. The firm has a 50 day simple moving average of $7.27 and a 200-day simple moving average of $6.65.

Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.14. Inogen had a negative return on equity of 42.87% and a negative net margin of 30.07%. The firm had revenue of $78.03 million during the quarter, compared to analysts' expectations of $73.67 million. During the same quarter last year, the firm posted ($0.63) earnings per share. The company's revenue for the quarter was up 8.1% compared to the same quarter last year. Equities analysts predict that Inogen, Inc. will post -2.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Kent Lake Capital LLC acquired a new position in shares of Inogen during the third quarter valued at about $2,418,000. Acadian Asset Management LLC raised its stake in shares of Inogen by 195.6% in the third quarter. Acadian Asset Management LLC now owns 389,792 shares of the medical technology company's stock worth $2,033,000 after purchasing an additional 257,940 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Inogen by 347.2% in the fourth quarter. Federated Hermes Inc. now owns 265,485 shares of the medical technology company's stock worth $1,458,000 after purchasing an additional 206,125 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Inogen by 73.9% in the third quarter. Assenagon Asset Management S.A. now owns 225,730 shares of the medical technology company's stock valued at $1,178,000 after purchasing an additional 95,913 shares in the last quarter. Finally, Meros Investment Management LP boosted its position in shares of Inogen by 14.9% during the third quarter. Meros Investment Management LP now owns 589,604 shares of the medical technology company's stock valued at $3,078,000 after buying an additional 76,294 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on INGN shares. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a research report on Wednesday, May 8th. William Blair upgraded Inogen from a "market perform" rating to an "outperform" rating in a report on Thursday, February 15th. Finally, Stifel Nicolaus raised their price objective on shares of Inogen from $6.00 to $7.00 and gave the stock a "hold" rating in a research report on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $7.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.